NasdaqCM - Delayed Quote USD

GeoVax Labs, Inc. (GOVX)

1.0300

-0.1100

(-9.65%)

At close: June 13 at 4:00:02 PM EDT

1.1200

+0.09

+(8.74%)

After hours: June 13 at 7:59:39 PM EDT

GeoVax to Participate in BIO International Convention 2025

ATLANTA, GA - June 12, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO Interna...

NewMediaWire 3 days ago

GOVX
-9.65%

GOVXW
GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency

GEO-MVA Provides Potential Opportunity to Expand Mpox Vaccine Supply Amid Growing U.S. and Global Clade 1 Threat ATLANTA, GA - June 11, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-an...

NewMediaWire 4 days ago

GOVX
-9.65%

GOVXW
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients

ATLANTA, GA - June 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and solid tumors, today announced that clinical da...

NewMediaWire 5 days ago

GOVX
-9.65%

GOVXW
GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia

Preclinical Studies Demonstrate Durable Protection Against SARS-CoV-2 Variants, Including Omicron XBB.1.5, Driven by T-Cell Responses ATLANTA, GA - June 9, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology compan...

NewMediaWire 6 days ago

GOVX
-9.65%

GOVXW
GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology

Data from Two Key Studies Highlight CrossReactivity and BroadSpectrum Immunity of GEO-CM04S1 and GeoVax Multi-Antigen Vaccine Technology ATLANTA, GA - June 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology com...

NewMediaWire 11 days ago

GOVX
-9.65%

GOVXW
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing

Highlights Broad National Support for Domestic Vaccine Resilience and Role of MVA Platform in Public Health Preparedness ATLANTA, GA - May 29, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing ...

NewMediaWire 17 days ago

GOVX
-9.65%

GOVXW
GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance

Highlights Critical Role of Multi-Antigen GEO-CM04S1 in Protecting Vulnerable Populations ATLANTA, GA - May 27, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immu...

NewMediaWire 19 days ago

GOVX
-9.65%

GOVXW
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation

GeoVax's Advanced MVA Manufacturing Platform Supports ASPR-DARPA Vision for Scalable, AI-Integrated Pharmaceutical Production ATLANTA, GA - May 21, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company focused...

NewMediaWire 25 days ago

GOVX
-9.65%

GOVXW
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations

GEO-CM04S1 Demonstrates Superior Protection in Immunocompromised Populations; Fully Aligned with HHS Priorities for Durable, Broad-Spectrum Immunization ATLANTA, GA - May 20, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage bi...

NewMediaWire 26 days ago

GOVX
-9.65%

GOVXW
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025

GEO-CM04S1 Demonstrates Robust COVID-19 and Mpox Immunogenicity in Immunocompromised Patients and Healthy Adults ATLANTA, GA - May 8, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunother...

NewMediaWire last month

GOVX
-9.65%

GOVXW
GeoVax Expands Gedeptin(R) Patent Portfolio

Allowed Patent Claims Cover the Synergistic Combination of Gedeptin(R) Therapy with Radiation As a Targeted Approach for Solid Tumors ATLANTA, GA - May 7, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company ...

NewMediaWire last month

GOVX
-9.65%

GOVXW
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production

Company's Advanced Manufacturing Proposal Supports National Biosecurity Goals and Executive Action on Domestic Pharmaceutical Supply Chains ATLANTA, GA - May 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology co...

NewMediaWire last month

GOVX
-9.65%

GOVXW
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update

COVID-19 vaccine program progressing with additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in second quarter of 2025 Clinical evaluation of GEO-MVA, vaccine candidate for protection against Mpox and Smallp...

NewMediaWire last month

GOVX
-9.65%

GOVXW
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting

Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin's Potential in Solid Tumors ATLANTA, GA - April 29, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunother...

NewMediaWire last month

GOVX
-9.65%

GOVXW
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater

GEO-MVA Advancing as the Leading U.S.-Developed Mpox Vaccine Candidate ATLANTA, GA - April 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious disea...

NewMediaWire last month

GOVX
-9.65%

GOVXW
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress

GEO-CM04S1 Demonstrates Durable T Cell and Antibody Responses in Healthy and Immunocompromised Populations ATLANTA, GA - April 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and ...

NewMediaWire last month

GOVX
-9.65%

GOVXW
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA - April 23, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today ...

NewMediaWire last month

GOVX
-9.65%

GOVXW
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations

Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities ATLANTA, GA - April 22, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunot...

NewMediaWire last month

GOVX
-9.65%

GOVXW
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates

Peer-Reviewed Data Reinforces GeoVax's Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical Programs ATLANTA, GA - April 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology compan...

NewMediaWire last month

GOVX
-9.65%

GOVXW
GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $14 from $18 and keeps a Buy rating on the shares. GeoVax has encountered a significant challenge following the termination of its BARDA-funded Phase 2b clinical trial for the GEO-CM04S1 COVID-19 vaccine, the firm says. This decision, made for the government’s convenience, halts a pivotal study that was set to evaluate GEO-CM04S1 against an approved mRNA vaccine in a 10,000-participant trial under Project NextGen. The abru

TipRanks last month

GOVX
-9.65%

GOVXW

Performance Overview

Return	GOVX	S&P 500 (^GSPC)
YTD	-58.30%	+1.62%
1-Year	-26.43%	+10.00%
3-Year	-94.03%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GeoVax Labs, Inc. (GOVX)

GeoVax to Participate in BIO International Convention 2025

GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency

GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients

GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia

GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology

GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing

GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance

GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation

GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations

GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025

GeoVax Expands Gedeptin(R) Patent Portfolio

GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production

GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update

GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting

GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater

GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress

GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations

GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates

GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital

Performance Overview